RECRUITING Not applicable ClinicalTrials.gov

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Sponsor: Centre Jean Perrin • ClinicalTrials.gov ID: NCT07178847

Registry updated: 2026-09-11

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Interventions

blood sampling (Biological)
The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy

Eligibility criteria

Selection Criteria: * Patient included in NeckTAR study * Written informed consent signed for NeckTAR-IN study * Affiliation to the French social security system

Conditions

Locally Advanced Head and Neck Carcinoma

Locations

CH Henri Mondor Aurillac — Aurillac, CANTAL, France
Centre Jean PERRIN — Clermont-Ferrand, Puy-de-Dôme, France
Hôpital de la Croix-Rousse — Lyon, France
CHU de Saint-Étienne — Saint-Etienne, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment